Company Dossier · Biotech · Immunology
T-Cypher Bio
Oxford's TCR codebreakers - turning the immune system's own recognition machinery into a pipeline of cancer and autoimmune medicines.
Oxford's TCR codebreakers - turning the immune system's own recognition machinery into a pipeline of cancer and autoimmune medicines.
Somewhere in a building off Edmund Halley Road, a machine is sorting through T cells - thousands of them, each carrying a receptor that has already made a decision about what belongs in your body and what does not. Most of biotech tries to guess which targets matter. T-Cypher Bio does something quieter and stranger: it asks the T cells directly. The receptor is a password. The company built the reader.
That is the whole idea, compressed. The immune system already knows how to find cancer - the hard part has always been finding the exact T cell that knows, out of a repertoire so vast it makes a haystack look tidy. T-Cypher Bio, a roughly 43-person company spun out of Oxford science, treats that search as an engineering problem rather than a stroke of luck.
Figures compiled from public filings and third-party databases; funding total is an external estimate.
T-Cypher has the leading technology in the field for deconvoluting vast T cell repertoires.
T-Cypher Bio's advantage isn't one clever molecule - it's a workflow. Wet-lab immunology feeds computation, computation narrows the search, and the search points back at real patient T cells. Here's the stack.
The integrated discovery engine. It selects therapeutically relevant targets and pulls out potent, target-specific TCRs - working around the bottlenecks that have long made TCR discovery slow.
A microfluidic approach that tests TCR function directly from patient T cells. No T cell cloning. No fiddly soluble-TCR generation. Function, measured at scale.
Proprietary technology for mapping the immune synapse - the handshake between a T cell and its target - to reveal which antigens are truly worth chasing.
Peptide data tells the company what a cell is showing the world; AI and bioinformatics decide what it means. Together they turn immune biology into a searchable map.
In late 2020 the decision was made to separate. T-Cypher Bio broke off from Orbit Discovery - itself born of University of Oxford research - to chase one thing without distraction: TCR therapeutics. The formal launch came in February 2021, financed by Oxford Sciences Innovation with a syndicate of specialist backers who had followed the science from the start.
Solid tumours are the reason for the focus. They are hard precisely because they hide - their targets are subtle, shared with healthy tissue, or buried in a repertoire too large to brute-force. T-Cypher's answer is to let the immune system do the pointing. And because cancer and autoimmune disease turn out to rhyme at the level of the immune synapse - both come down to what a T cell decides to attack - the same platform runs both programmes.
The best target is the one your own T cells already chose.
It's a pun that happens to be a mission statement. T cells plus cipher: a company built to decrypt the code T cells use to recognise disease. The name is the strategy.
Roles per public company sources; leadership at an early-stage biotech shifts - treat as a snapshot.
The end goal: TCR-based medicines for cancers - and immune-mediated diseases - that current options don't reach.
A B2B drug developer. Its platform and pipeline are the basis for partnership and licensing conversations with larger players.
A working proof that repertoire-first, function-first discovery can be industrialised - relevant to anyone studying T cell specificity.
Back in that Oxford lab, the machine is still sorting T cells. But the room has changed. What used to be a needle-in-a-haystack problem - find the one receptor that recognises a tumour - is now a queue, a readout, a shortlist. The password isn't a mystery to be lucked into; it's data to be read. T-Cypher Bio didn't make the immune system smarter. It made the immune system legible. And for a patient waiting on the far end of that pipeline, legible is exactly the word that matters.
No official company YouTube channel or product-demo video was found in public sources at time of writing.